President Trump announced nine more companies joining TrumpRx, aiming for U.S.-Europe drug price parity using tariffs as leverage. TrumpRx will offer future drug releases at most-favored-nation ...
On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain foreign biotechnology companies viewed as national security risks. The measure ...
BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and ...
Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results